BioNTech Results Presentation Deck

Q3 2020 Highlights BNT 162 COVID-19 Vaccine Program 4 Oncology Pipeline Financial Update and Outlook 1 ● ● ● Achieved Success in First Interim Analysis from Phase 3 Study No serious adverse events with mild to moderate tolerability profile observed to date Rolling submissions ongoing to EMA, MHRA (UK) and Health Canada On track for Emergency Use Authorization submission to FDA as early as the third week of November ● Initiated clinical trials in Japan and China to support potential local approval Acquired GMP facility in Marburg, Germany intended to increase production capacity in 2021 Commercial launch planning underway with global partners Pfizer and Fosun Pharma Promising early Phase 1 data for Next Gen Immunomodulator (BNT311) at SITC 2020 Early Phase 1 data presented for BNT131 (SAR 441000) at SITC and BNT114 at ESMO IND approval granted for randomized Phase 2 trial of iNeST (BNT122) in adjuvant CRC First patient dosed in Phase 1/2a trial of BNT411 in SCLC Closed equity and debt financings and secured grant commitments of approximately $1.2 billion¹ (€1.0 billion) in combined gross proceeds, resulting in net cash receipts of $0.8 billion¹ (€0.6 billion) in the third quarter Cash position of $1.2 billion¹ (€1.0 billion) on the balance sheet at end of Q3 2020 Amounts translated using the exchange rate published by the German Central Bank (Deutsche Bundesbank) in effect as of the date of transaction, if closed; otherwise as of September 30, 2020 BIONTECH

View entire presentation